Diagnosis and Treatment of Pelvic Inflammatory Disease in Pregnancy

Diagnosis

The Centers for Disease Control and Prevention (CDC) recommends that the clinical presentation of pelvic inflammatory disease (PID) in pregnant women should meet specific diagnostic criteria, including bilateral adnexal tenderness in a sexually active woman, with additional supportive criteria such as purulent vaginal discharge and white blood cells on urinalysis 1, 2, 3, 4
The American College of Obstetricians and Gynecologists (ACOG) and CDC guidelines emphasize the importance of prompt diagnosis and treatment of PID in pregnant women to prevent maternal morbidity, fetal loss, and preterm delivery 1, 2

The CDC recommends that pregnant women with suspected PID must be hospitalized and treated with parenteral antibiotics to provide empiric broad-spectrum coverage against Neisseria gonorrhoeae, Chlamydia trachomatis, anaerobes, and gram-negative facultative bacteria 1, 2, 4
The recommended parenteral options for hospitalized patients include extended-spectrum cephalosporin (e.g., ceftriaxone) plus azithromycin, as doxycycline is contraindicated in pregnancy 1, 2

The CDC guidelines recommend that parenteral therapy should be continued until 24 hours after clinical improvement, with expected substantial improvement within 3 days of starting therapy 1, 2
If no improvement occurs within 72 hours, re-evaluation of the diagnosis, consideration of imaging for tubo-ovarian abscess, and potentially surgical intervention are recommended 1, 2

The CDC recommends that male sex partners of pregnant women with PID must be examined and treated if they had sexual contact within 60 days before symptom onset, due to the high likelihood of urethral gonococcal or chlamydial infection in partners 1, 2